The UA Campus Repository is experiencing systematic automated, high-volume traffic (bots). Temporary mitigation measures to address bot traffic have been put in place; however, this has resulted in restrictions on searching WITHIN collections or using sidebar filters WITHIN collections. You can still Browse by Title/Author/Year WITHIN collections. Also, you can still search at the top level of the repository (use the search box at the top of every page) and apply filters from that search level. Export of search results has also been restricted at this time. Please contact us at any time for assistance - email repository@u.library.arizona.edu.
Comparative Mid-term Outcomes of Pediatric Hematogenous Methicillin-resistant Staphylococcus aureus and Methicillin-susceptible Staphylococcus aureus osteomyelitis
| dc.contributor.author | Blank, Tiana | |
| dc.date.accessioned | 2018-03-28T22:49:00Z | |
| dc.date.available | 2018-03-28T22:49:00Z | |
| dc.date.issued | 2018-03-28 | |
| dc.identifier.uri | http://hdl.handle.net/10150/627148 | |
| dc.description | A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. | en |
| dc.description.abstract | The bacteria staphylococcus aureus is the most common etiology of acute hematogenous osteomyelitis (AHO) in healthy pediatric patients, accounting for 70-90% of cases. • AHO occurs at a rate of 1/10,000 pediatric patients/year. • Increasing prevalence of community-acquired methicillin resistant staph aureus (MRSA) is leading to a concurrent rise of such invasive pediatric infections in the US. • MRSA AHO on average have longer hospital stays, more febrile days, longer antibiotic therapy, and increase in overall complications vs. methicillin sensitive staph aureus (MSSA). • There is a lack of data on the functional outcome of these patients beyond 2 years post index infection. • Goal of study: compare treatment and midterm (2 years post index infection) functional outcomes between patients with MRSA vs. MSSA infections, and localized vs. disseminated infections. • Hypothesis: treatment and outcomes between MRSA and MSSA, and localized and disseminated, will be different, specifically that MRSA and disseminated will have worse midterm functional outcomes | |
| dc.language.iso | en_US | en |
| dc.publisher | The University of Arizona. | en_US |
| dc.rights | Copyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. | en_US |
| dc.subject.mesh | Methicillin-Resistant Staphylococcus aureus | en |
| dc.subject.mesh | Osteomyelitis | en |
| dc.title | Comparative Mid-term Outcomes of Pediatric Hematogenous Methicillin-resistant Staphylococcus aureus and Methicillin-susceptible Staphylococcus aureus osteomyelitis | en_US |
| dc.type | text; Electronic Thesis | en |
| dc.contributor.department | The University of Arizona College of Medicine - Phoenix | en |
| dc.description.collectioninformation | This item is part of the College of Medicine - Phoenix Scholarly Projects 2018 collection. For more information, contact the Phoenix Biomedical Campus Library at pbc-library@email.arizona.edu. | en_US |
| dc.contributor.mentor | Belthur, Mohan | en |
| refterms.dateFOA | 2018-09-12T07:07:14Z | |
| html.description.abstract | The bacteria staphylococcus aureus is the most common etiology of acute hematogenous osteomyelitis (AHO) in healthy pediatric patients, accounting for 70-90% of cases. • AHO occurs at a rate of 1/10,000 pediatric patients/year. • Increasing prevalence of community-acquired methicillin resistant staph aureus (MRSA) is leading to a concurrent rise of such invasive pediatric infections in the US. • MRSA AHO on average have longer hospital stays, more febrile days, longer antibiotic therapy, and increase in overall complications vs. methicillin sensitive staph aureus (MSSA). • There is a lack of data on the functional outcome of these patients beyond 2 years post index infection. • Goal of study: compare treatment and midterm (2 years post index infection) functional outcomes between patients with MRSA vs. MSSA infections, and localized vs. disseminated infections. • Hypothesis: treatment and outcomes between MRSA and MSSA, and localized and disseminated, will be different, specifically that MRSA and disseminated will have worse midterm functional outcomes |
